Prevalence of high-risk metabolic dysfunction-associated fatty liver disease (MASH) according to the FAST® index in a group of diabetic patients
Introduction and Objectives: Diabetes is a high-risk condition for the progression of metabolic-associated fatty liver disease (MASLD). The FAST index combines the FibroScan® and AST to predict the risk of high-risk metabolic dysfunction-associated steatohepatitis (MASH). Objective: determine the pr...
Saved in:
| Main Authors: | Kevin S. Vázquez-Hernández, Andres Burak-Leipuner, Alfredo I. Servin-Caamaño, Javier A. Romero-Bermúdez, Laura E. Ceceña-Martínez, José L. Pérez-Hernández, María C. Castañeda-Aguilar, Fátima Higuera-de la Tijera |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | Annals of Hepatology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268125000407 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prevalence of fibrosis and steatosis determined by transient elastography and controlled attenuation parameter (Fibroscan®) in diabetic patients
by: Kevin S. Vázquez-Hernández, et al.
Published: (2025-04-01) -
Validation of the diagnostic accuracy of the acFibroMASH index for at-risk MASH in patients with metabolic dysfunction-associated steatotic liver disease
by: Yunfei Wu, et al.
Published: (2025-03-01) -
Evaluation of oxidative stress according to the pattern of alcohol consumption and in alcoholic liver disease.
by: Adrián Flores-Sánchez, et al.
Published: (2025-04-01) -
Global research initiative for patient screening on MASH (GRIPonMASH) protocol: rationale and design of a prospective multicentre study
by: Manuel Castro Cabezas, et al.
Published: (2025-05-01) -
FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
by: Muhammad Mazhar Azam, et al.
Published: (2024-12-01)